State of New Jersey Common Pension Fund D Purchases 4,351 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

State of New Jersey Common Pension Fund D increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,692 shares of the company’s stock after acquiring an additional 4,351 shares during the period. State of New Jersey Common Pension Fund D owned about 0.05% of CRISPR Therapeutics worth $1,759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Allworth Financial LP boosted its stake in shares of CRISPR Therapeutics by 2,117.4% during the fourth quarter. Allworth Financial LP now owns 15,078 shares of the company’s stock valued at $593,000 after purchasing an additional 14,398 shares in the last quarter. Congress Asset Management Co. increased its position in CRISPR Therapeutics by 4.5% in the 4th quarter. Congress Asset Management Co. now owns 68,739 shares of the company’s stock valued at $2,706,000 after acquiring an additional 2,971 shares during the period. Van ECK Associates Corp raised its stake in shares of CRISPR Therapeutics by 5,269.3% during the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after acquiring an additional 81,464 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in shares of CRISPR Therapeutics by 3.2% during the fourth quarter. Capital Advisors Inc. OK now owns 310,270 shares of the company’s stock worth $12,212,000 after purchasing an additional 9,681 shares during the period. Finally, Kestra Private Wealth Services LLC grew its stake in shares of CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock worth $812,000 after purchasing an additional 310 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several recent research reports. The Goldman Sachs Group decreased their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Finally, TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $74.40.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $44.51 on Wednesday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $90.62. The stock has a market cap of $3.82 billion, a PE ratio of -10.19 and a beta of 1.67. The stock has a 50-day moving average of $42.29 and a two-hundred day moving average of $46.00.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.